Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin-Frankfurt-Münster (BFM) protocols

Blood Coagulation and Fibrinolysis

Volumn 23, Issue 2, 2012, Pages 144-154

  Lejhancova Tousovska, Katerina ^a,b   Zapletal, Ondrej ^c   Vytiskova, Sona ^d   Strbackova, Petra ^d   Sterba, Jaroslav ^d,e  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c Department of Pediatric Hematology ^*  (Czech Republic)

^d University Hospital   (Czech Republic)

^e MASARYK UNIVERSITY   (Czech Republic)

Author keywords

acute lymphoblastic leukemia; chemotherapy; pediatric hematology oncology; thrombin generation; thrombosis

Indexed keywords

ANTITHROMBIN; ASPARAGINASE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; FIBRINOGEN; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANTITHROMBIN DEFICIENCY; ARTICLE; AUTOMATION; BERLIN FRANKFURT MUNSTER PROTOCOL; BLOOD SAMPLING; CALIBRATION; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; HUMAN; HYPOFIBRINOGENEMIA; INFECTION; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STATISTICAL SIGNIFICANCE; THROMBIN TIME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOMATION; BLOOD COAGULATION TESTS; CALIBRATION; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBIN;

EID: 84856593369     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32834fb539     Document Type: Article

References (54)

1. Stary J. Fifty years of successful treatment of childhood acute lymphoblastic leukemia. Ces-slov Pediat 2007; 62:540-545.
2. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Mö ricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AEIOP-BFM ALL 2000 study. Blood 2010; 115:3206-3214.
3. Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of disease and therapy. Thromb Res 2003; 111:199-212. (Pubitemid 38021936)
4. Attarbaschi A, Mann G, Kronberger M, Witt V, Gadner H, Dworzak M. Effects of dose-reduced Medac L-asparaginase on coagulation in trial ALL-BFM 2000. Klin Padiatr 2003; 215:321-326. (Pubitemid 38064630)
5. Mitchell LG, the PARKAA Group. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase. Cancer 2003; 97:508-516.
6. Kieslich M, Porto L, Lanfermann H, Jacobi G, Schwabe D, Böhles H. Cerebrovascular complication of L-asparaginase in the therapy of acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2003; 25:484-487. (Pubitemid 36682755)
7. Fleischhack G, Solymosi L, Reiter A, Bender-Götze C, Eberl W, Bode U. Imaging methods in diagnosis of cerebrovascular complications with L-asparaginase therapy. Klin Padiatr 1994; 204:264-273.
8. Abbott LS, Deevska M, Fernandez CV, Dix D, Price VE, Wang H, et al. The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase. Blood 2009; 114:5146-5151.
9. Appel IM, Hop WC, van Kessel-Bakvis C, Stigter R, Pieters R. L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia. Thromb Haemost 2008; 100:330-337.
10. Mitchell LG, Andrew M, Hanna K, Abshire T, Halton J, Wu J, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving L-asparaginase for acute lymphoblastic leukemia. Thromb Haemost 2003; 90:235-244. (Pubitemid 36992499)
11. Oner AF, Gurgey A, Kirazli S, Okus H, Tunç B. Changes of hemostatic factors in children with acute lymphoblastic leukemia receiving combined chemotherapy including high dose methylprednisolone and L-asparaginase. Leuk Lymphoma 1999; 33:361-364. (Pubitemid 29196873)
12. Appel IM, Hop WCJ, Pieters R. Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases. Blood Coagul Fibrinolysis 2006; 17:139-146.
13. Athale UH, Siciliano SA, Crowther M, Barr RD, Chan AK. Thrombembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. Br J Haematol 2005; 129:803-810. (Pubitemid 40904532)
14. Nowak-Göttl U, Heinecke A, von Kries R, Nürnberger W, Münchow N, Junker R. Thrombotic events revisited in children with acute lymphoblastic leukemia. Impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res 2001; 103:165-172. (Pubitemid 32728101)
15. Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Mariani G, deGaetano G, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006; 108:2216-2222. (Pubitemid 44497502)
16. Möricke A, Zimmermann M, Greiner J, Schrauder A, Stanulla M, Attarbaschi A, et al. Prospective evaluation of thromboembolic events during chemotherapy of childhood lymphoblastic leukemia: results of randomized trial ALL-BFM 2000. Blood 2009; 114(22s):abstract 990.
17. Nowak-Göttl U, Wermes C, Junker R, Koch HG, Schobess R, Fleischhack G, et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 1999; 93:1595-1599. (Pubitemid 29102487)
18. Mitchell LG, Lambers M, Flege S, Kenet G, Li-Thiao-Te V, Holzhauer S, et al. Validation of a predictive model for identifying an increased risk for thrombembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood 2010; 115:4999-5004.
19. Halton JM, Mitchell LG, Vegh P, Eves M, Andrew ME. Fresh frozen plasma has no beneficial effect on the hemostatic system in children receiving L-asparaginase. Am J Hematol 1994; 47:157-161. (Pubitemid 24333440)
20. Elhasid R, Lanir N, Sharon R, Weyl Ben Arush M, Levin C, Postovsky S, et al. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis 2001; 12:367-370. (Pubitemid 32730495)
21. Giordano P, Del Vecchio GC, Santoro N, Arcamone G, Coppola B, Altomare M, et al. Thrombin generation in children with acute lymphoblastic leukemia: effect of leukemia immunophenotype subgroup. Pediatr Hematol Oncol 2000; 17:667-672.
22. Atahale U, Moghrabi A, Nayiager T, Yves-Line D, Thabane L, Chan A. Circulating blasts are associated with high levels of vWF and thrombin activation in children with newly diagnosed ALL. Blood 2008; 112(11s):abstract 1824.
23. Hemker HC, Willems GM, Béguin S.A computer assisted method toobtain the prothrombin activation velocity in whole plasma independent of thrombin decay process. Thromb Haemost 1986; 56:9-17. (Pubitemid 16015908)
24. Hemker HC, Giesen P, AlDieri R, Regnault V, deSmedt E, Wagenvoord E, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33:4-15. (Pubitemid 37449290)
25. Tripodi A, Martinelli I, Chantarangkul V, Battaglioli T, Clerici M, Mannucci PM. The endogenous thrombin potential and the risk of venous thrombembolism. Thromb Res 2007; 121:353-359.
26. Besser M, Baglin C, Luddington R, van Hylckama Vlieg A, Baglin T. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost 2008; 6:1720-1725.
27. Tripodi A, Legnani C, Chantarangkul V, Cosmi B, Palareti G, Mannucci PM. High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thrombembolism. J Thromb Haemost 2008; 6:1327-1333. (Pubitemid 352016312)
28. Tripodi A, Legnani C, Palareti G, Chantarangkul V, Mannucci PM. More on high thrombin generation and the risk of recurrent venous thrombembolism. J Thromb Haemost 2009; 7:906-907.
29. Tripodi A, Primignani M, Chantarangkul V, Clerici M, DellEra A, Fabris F, et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006; 44:440-445. (Pubitemid 44214883)
30. Dargaud Y, Bé guin S, Lienhart A, AlDieri R, Trzeciak C, Bordet JC, et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93:475-480. (Pubitemid 40392535)
31. Brummel-Ziedins KE, Whelihan MF, Gissel M, Mann KG, Rivard GE. Thrombingeneration andbleedinginhaemophiliaA.Haemophilia2009;1-8.
32. DevreeseK,WijnsW,Combes I,Van kerckhovenS,Hoylaerts MF. Thrombin generation in plasma of healthy adults and children: chromogenic versus fluorogenic thrombogram analysis. Thromb Haemost 2007;98: 600-613. (Pubitemid 47412886)
33. Haidl H, Cimenti C, Leschnik B, Zach D, Muntean W. Age-dependency of thrombin generation measured by means of calibrated automated thrombography (CAT). Thromb Haemost 2006; 95:772-775.
34. Yamashita A, Nagae C, Muto S, Asahara M, Morimoto M, Kondo K, et al. Effects of L-asparaginase therapy on thrombin generation in children with acute leukemia. J Thromb Haemost 2009; 7(s2):149PP-MO-439.
35. Stief TW, Otto S, Renz H. The intrinsic coagulation activity assay. Blood Coagul Fibrinolysis 2006; 17:369-378. (Pubitemid 43941579)
36. Stief TW. Inhibition of thrombin generation in recalcified plasma. Blood Coagul Fibrinolysis 2007; 18:751-760. (Pubitemid 350059334)
37. Stief TW, Chalkitis D. Asparaginase may trigger thrombin generation. Hemost Lab 2008; 2:139-197.
38. Dargaud Y, Luddington R, Gray E, Negrier C, Lecompte T, Petros S, et al. Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study. Br J Haematol 2007; 139:303-309. (Pubitemid 47493090)
39. Rice M, Bell BA, Chauvenet A, Kurtzberg J, Abish SB, Pullen J, et al. Thrombotic and hemorrhagic events for patients on Pediatric Oncology Group (POG) protocols 9201, 9605, 9406. Blood 2005; 106:abstract 880.
40. Piatkowska-Jakubas B, Krawczyk-Kulis M, Giebel S, Adamzyk-Cioch M, Czyz A, Lech Maranda E, et al. Use of L-asparginase in acute lymphoblastic leukemia: recommendation of the Polish Adult Leukamia Group. Pol Arch Med Wewn 2008; 118:664-667.
41. Nowak-Göttl U, Rath B, Binder M, Hassel JU, Wolff J, Husemann S, et al. Inefficacy of fresh frozen plasma in the treatment of L-asparaginase induced coagulation factor deficiencies during ALL induction therapy. Haematologica 1995; 80:451-453.
42. Meister B, Kropshofer G, Klein-Franke A, Strasak AM, Hager J, Streif W. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thrombembolism in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2008; 50:298-303.
43. Schols SM, Lancé MD, Feijge MA, Damoiseaux J, Marcus MA, Humulyák K, et al. Impaired thrombin generation and fibrin clot formation in patients with dilutional coagulopathy during major surgery. Thromb Haemost 2010; 103:318-328.
44. Reinhofer M, Brauer M, Franke U, Barz D, Marx G, Lösche W. The value of rotation thrombelastometry to monitor disturbed perioperative haemostasis and bleeding risk in patients with cardiopulmonary bypass. Blood Coagul Fibrinolysis 2008; 19:212-219. (Pubitemid 351498725)
45. Nowak-Göttl U, Kenet G, Mitchell LG. Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, etiology, diagnosis, prevention and treatment. Best Pract Res Clin Haematol 2009; 22:103-114.
46. Nowak-Göttl U, Ahlke E, Schulze-Westhoff P, Boos J. Changes in coagulation and fibrinolysis in childhood ALL: a two step dose reduction of one E. coli asparaginase preparation. Br J Haematol 1996; 95:123-126. (Pubitemid 26340239)
47. Vieira Pinheiro JP, Ahlke E, Nowak-Gö ttl U, Hempel G, Müller HJ, Lümkemann K, et al. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the pediatric ALL/NHL-BFM treatment protocols. Br J Haematol 1999; 104:313-320. (Pubitemid 29083340)
48. Hempel G, Müller HJ, Lanvers-Kaminsky C, Würthwein G, Hoppe A, Boos J. A population pharmacokinetic model for pegylated-asparaginase in children. Br J Haematol 2009; 148:119-125.
49. Wenner] KA, Vieira Pinheiro JP, Escherich G, Wessalowski R, Jorch N, Wolff J, et al. Asparagine concentration in plasma after 2 500IU/m(2)PEG- asparaginase i.v. in children with acute lymphoblastic leukemia. Klin Padiatr 2005; 217:321-326. (Pubitemid 41746113)
50. Collins PW, Macchiavello LI, Lewis SJ, Macartney NJ, Saayman AG, Luddington R, et al. Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. Br J Haematol 2006; 135:220-227. (Pubitemid 44401620)
51. Amaral A, Opal SM, Vincent JL. Coagulation in sepsis. Int Care Med 2004; 30:1032-1040. (Pubitemid 38833353)
52. Mavrommatis AC, Theodoridis T, Orfanidou A, Roussos C, Christopoulou-Kokkinou V, Zakynthinos S. Coagulation system and platelets are fully activated in uncomplicated sepsis. Crit Care Med 2000; 28:451-457. (Pubitemid 30120888)
53. Levi M. The coagulant response in sepsis and inflammation. Hamostaseologie 2010; 30:10-16.
54. Stief TW. Thrombin generation by exposure of blood to endotoxin: a simple model to study disseminated intravascular coagulation. Clin Appl Thromb Hemost 2006; 12:137-161. (Pubitemid 44400856)